OnCo
institutionsInstitution

Georgetown Lombardi Comprehensive Cancer Center

The only NCI comprehensive cancer centre in Washington, DC, known for breast cancer research including leadership of the CLEOPATRA pertuzumab trial.

NCI-designated since 1974, Georgetown Lombardi is Washington's only comprehensive cancer centre and since 2019 has formed a consortium with Hackensack Meridian's John Theurer Cancer Center in New Jersey. Breast cancer has been its signature: Marc Lippman and Robert Clarke built the hormone-receptor and endocrine-resistance programme, and Sandra Swain led CLEOPATRA, which established pertuzumab plus trastuzumab and docetaxel as first-line therapy for HER2-positive metastatic breast cancer. Louis Weiner's antibody immunotherapy laboratory and a cancer-prevention and population-science programme focused on the DC region round out the portfolio. Care is delivered at MedStar Georgetown University Hospital.

Location
Washington, DC, US
Type
cancer center · Georgetown University
Newsweek 2026 oncology rank
Not in top 300 listing used
NCI designation
comprehensive
OnCo score
#88 · 35 points (0 Newsweek + 15 NCI + 20 from 10 linked objects) · ranking

Programmes

3top
  • Breast cancer (CLEOPATRA)
  • Antibody immunotherapy
  • Consortium with John Theurer Cancer Center

Connected

10top

Pages like this

not linked directly; found by shared links